Please login to the form below

Not currently logged in
Email:
Password:

Creabilis names Catherine Moukheibir as chairman of the board

She has previously held roles at Ablynx, Movetis and Innate Pharma

edit-Creabilis-Catherine-MoukheibirDermatology firm Creabilis has appointed Catherine Moukheibir as chairman of its board of directors.

Moukheiber will head the board as it progresses its lead product CT327, a first-in-class selective TrkA kinase inhibitor for the treatment of pruritus (itching) due to psoriasis.

Commenting on her appointment, Moukheibir said: “I am delighted to have been appointed to lead the Creabilis Board at this important time in the Company's development. 

“The potential of CT327 in the treatment of pruritic conditions is a significant opportunity and the data reported so far demonstrates the power of Creabilis' pipeline and its unique low systemic exposure platform technology.”

Moukheibir has a wide range of experience in aligning corporate goals with financial strategy. 

After an initial career in strategy consulting and investment banking, she held a number of senior management role at European biotech firms including CFO at Movetis, non-executive board member at Ablynx and member of the management board at Innate Pharma.

Last November, Moukheiber was also named as an observer to Zealand's board of directors.

2nd June 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics